Browse result page of CancerPDF Database
Please click on CancerPDF_ID for detailed information about peptide.
| CancerPDF_ID | Peptide seq | Protein Name | Fluid | Mass/Z | Profiling Technique | Cancer Type | Expression Regulation | PUBMED ID |
|---|---|---|---|---|---|---|---|---|
| CancerPDF_ID20 | SSSYSKQFTSSTSYNRGDSTFESKSYKMADEAGSEADHEGTHSTKRGHAKSRPV | Fibrinogen alpha chain | Serum | 5901.7 | MALDI-TOF | Metastatic thyroid carcinomas | Differentially expressed between cancer vs normal samples | 16896061 |
| CancerPDF_ID3518 | GAGPGSGSnVSMNQQNPqAPQAqSLGGMHVNGAPPLMqASMQGGVPAPGQMP | Cleavage stimulation factor subunit 2 | Urine | NA | "CE-MS, Micro-TOF-MS" | Bladder cancer | Differentially expressed between primary UBC and normal individual | 27026199 |
| CancerPDF_ID3519 | DGETGAAGppGPAGPAGERGEqGAPGPSGFQGLPGPPGPPGEGGKpGDQGVPGEAGAPG | "Collagen alpha-1(II) chain, COL2A1" | Urine | NA | "CE-MS, Micro-TOF-MS" | Bladder cancer | Differentially expressed between primary UBC and normal individual | 27026199 |
| CancerPDF_ID3520 | IQRTPKIQVYSRHPAENGKSNFLNcYVSGFHPSDIEVDLLKNGERIEKVEHSDLSFSKDWSFYLLYYTEFTPTEKDEYAcRVNHVTLSQPKIVKWDRDM | Beta-2-microglobulin | Urine | NA | "CE-MS, Micro-TOF-MS" | Bladder cancer | Differentially expressed between primary UBC and normal individual | 27026199 |
| CancerPDF_ID3521 | IQRTPKIQVYSRHPAENGKSNFLNcYVSGFHPSDIEVDLLKNGERIEKVEHSDLSFSKDWSFYLLYYTEFTPTEKDEYAcRVNHVTLSQPKIVKWDRDm | Beta-2-microglobulin | Urine | NA | "CE-MS, Micro-TOF-MS" | Bladder cancer | Differentially expressed between primary UBC and normal individual | 27026199 |
| CancerPDF_ID3835 | GAGPGSGSnVSMNQQNPqAPQAqSLGGMHVNGAPPLMqASMQGGVPAPGQMP | Cleavage stimulation factor subunit 2 | Urine | NA | "CE-MS, Micro-TOF-MS" | Bladder cancer | Differentially expressed between recurrence of UBC vs recurrence control | 27026199 |
| CancerPDF_ID3837 | DGETGAAGppGPAGPAGERGEqGAPGPSGFQGLPGPPGPPGEGGKpGDQGVPGEAGAPG | "Collagen alpha-1(II) chain, COL2A1" | Urine | NA | "CE-MS, Micro-TOF-MS" | Bladder cancer | Differentially expressed between recurrence of UBC vs recurrence control | 27026199 |
| CancerPDF_ID3846 | IQRTPKIQVYSRHPAENGKSNFLNcYVSGFHPSDIEVDLLKNGERIEKVEHSDLSFSKDWSFYLLYYTEFTPTEKDEYAcRVNHVTLSQPKIVKWDRDM | Beta-2-microglobulin | Urine | NA | "CE-MS, Micro-TOF-MS" | Bladder cancer | Differentially expressed between recurrence of UBC vs recurrence control | 27026199 |
| CancerPDF_ID3847 | IQRTPKIQVYSRHPAENGKSNFLNcYVSGFHPSDIEVDLLKNGERIEKVEHSDLSFSKDWSFYLLYYTEFTPTEKDEYAcRVNHVTLSQPKIVKWDRDm | Beta-2-microglobulin | Urine | NA | "CE-MS, Micro-TOF-MS" | Bladder cancer | Differentially expressed between recurrence of UBC vs recurrence control | 27026199 |
| CancerPDF_ID8424 | SSSYSKQFTSSTSYNRGDSTFESKSYKMADEAGSEADHEGTHSTKRGHAKSRPV | Fibrinogen alpha | Serum | 5905.24 | MALDI-TOF | "Breast cancer, Lung cancer, Rectal cancer" | Frequency of peptide In lung cancer : 78.57% ; In Rectal cancer : 86.11% ; Breast cancer: 72%; In normal healthy individuals : 80.6% | 23667664 |
| CancerPDF_ID8523 | SSSYSKQFTSSTSYNRGDSTFESKSYKMADEAGSEADHEGTHSTKRGHAKSRPV | Fibrinogen alpha | Serum | 5900.7 | MALDI-TOF | "Breast cancer, Lung cancer, Rectal cancer" | NA | 23667664 |
| CancerPDF_ID8618 | TPDVSSALDKLKEFGNTLEDKARELISRIKQSELSAKMREWFSETFQKVKEKLKIDS | Apolipoprotein C-I precursor | Serum | 6625.91 | MALDI-TOF | Breast cancer | Downregulated in cancer as compare to normal control with fold change of 1.5 | 26705257 |
| CancerPDF_ID8620 | ARLAEYHAKATEHLSTLSEKAKPALEDLRQGLLPVLESFKVSFLSALEEYTKKLNTQ | Apolipoprotein A-I precursor | Serum | 6428.21 | MALDI-TOF | Breast cancer | Downregulated in cancer as compare to normal control with fold change of 1.7 | 26705257 |
| CancerPDF_ID8648 | ANDESNEHSDVIDSQELSKVSREFHSHEFHSHEDMLVVDPKSKEEDKHLKFRISHELDSASSEVN | Osteopontin ( C terminal fragment of protein OPN) | Cerbrospinal fluid | NA | MALDI-TOF | Glioblastoma (Malignant brain tumor) | Upregulated in cancer as compare to normal control | 19674866 |
| CancerPDF_ID8650 | MPMFIVNTNVPRASVPDGFLSELTQQLAQATGKPPQYIAVHVVPDQLMAFGGSSEPCALCSLHSIGKIGGAQNRSYSKLLCGLLAERLRISPDRVYINYYDMNAANVGWNNSTFA | Macrophage migration inhibitory protein | Serum | NA | FPLC | Bladder cancer | NA | 19762145 |
| CancerPDF_ID11035 | IHTGENPYECSECGKAFRYSSALVRHQRIHTGEKPLNGIGMSKSSLRVTTELN | zinc finger protein 3 | Serum | 5905.23 | MALDI-TOF | Clear cell renal carcinoma | "Upregulated in ccRCC, preoperative and post operative patients vs control" | 25368985 |
| CancerPDF_ID11052 | SSSYSKQFTSSTSYNRGDSTFESKSYKMADEAGSEADHEGTHSTKRGHAKSRPV | Fibrinogen alpha chain | Serum | 5900 | MALDI-TOF | Esophageal squamous cell carcinoma (ESCC) | Upregulated in patients vs normal with mean intensity 100.55 in normal and 831.12 in cancer | 26993605 |
| CancerPDF_ID11073 | SSSYSKQFTSST SYNRGDSTFESKSYKMADEAGSEADHEGTH STKRGHAKSR | Fibrinogen alpha chain | Blood | 5910 | MALDI-TOF | Gastric cancer | Upregulated in gastric patients vs healthy with 45.5±13.1 intesity in cancer patients and 9.2±4.7 intensity in normal pateints | 26662807 |
| CancerPDF_ID12851 | EAEEDGDLQCLCVKTTSQVRPRHITSLEVIKAGPHCPTAQLIATLKNGRKICLDLQAPLYKKIIKKLLES | Platelet factor 4 | Serum | NA | MALDI-TOF | Acute myeloid leukemia (AML) | Downregulated in AML vs healthy | 23915341 |